Paula Deen Has Public Support,Poll Shows

Despite her being excoriated in the media by everyone from rival chefs to a TV medical consultant with NBC Universal,a Yahoo poll shows the public isn't buying their bitter criticism of celebrity chef Paula Deen,who has persisted in presenting heavy Southern-style cuisine while hiding the fact that she suffers from type 2 diabetes.Asked whether she should be in the hot seat,62% of the Yahoo readers said no,people are being overly critical,while 38% said yes,she's a hypocrite.
Deen,who was diagnosed three years ago but kept the news to her family while she pondered her next move,has at the same time signed an endorsement contract with Danish pharma titan Novo Nordisk,maker of the flex pen insulin delivery device.Deen hosts the program "Paula's Best Dishes" on the Food Network cable channel.With her sons Bobby and Jamie,she is spearheading the "Diabetes in a New Light" campaign.It is an initiative to help adults find simple ways to manage everyday challenges of type 2 diabetes,the company said.
Resources of the initiative will include how to prepare diabetes-friendly food without compromising taste;incorporating physical activity into everyday life;managing stress;and working with your doctor to find a treatment plan that works for you.The Deens will create modified,diabetes-friendly versions of their favorite recipes and appear at diabetes cooking events across the country,according to Novo Nordisk.
Deen says she will also continue to present her beloved Southern cuisine for consumption in moderation.
Novo Nordisk(NVO)

Novo Nordisk Takes the Lead

Denmark's Novo Nordisk has a 51% share of the insulin market.It is their core business.In diabetes,the patient lacks enough insulin,or insulin of sufficient quality,to ensure that sugar reaches the cells rather than destructively remaining in the bloodstream.Diabetes is growing at an alarming rate,observed Lars Soerenson,Novo's CEO,which sets Novo apart from the rest of the pharmaceutical industry.
Novo's Victoza,which is delivered by a pen-like device,has insulin market leadership.It has been rolled out globally.The main treatment is a hormone.It's a balance between very powerful drugs and too low of an insulin level.Designer insulins reduce this problem.And the side effect profile is much better with designer insulins.
With poor treatment,Mr.Soerenson indicates,diabetes causes amputations,blindness and kidney disease,among other complications.Not treating it is very costly to society.Victoza costs 5-10 dollars per treatment.
The market is on the third generation of insulins.Novo Nordisk is in the lead now with the first new generation of designer insulins,Mr.Soerenson feels.
Novo Nordisk(NVO)